Skip to content

The Effect of Tegliadine Fumarate on Postoperative Nausea and Vomiting and Analgesia in Patients Undergoing Gynecological Laparoscopic Surgery

The Effect of Tegliadine Fumarate on Postoperative Nausea and Vomiting and Analgesia in Patients Undergoing Gynecological Laparoscopic Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118753
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting?Postoperative Pain

Interventions

Tegliadine Fumarate Group:0.02 mg/kg Tegliadine administered intravenously during induction, and 0.01 mg/kg Tegliadine administered intravenously 10 minutes before skin closure
Tegliadine Fumarate Group:0.02 µg/kg Sufentanil administered intravenously during induction, and 0.01 µg/kg Sufentanil administered intravenously 10 minutes before skin closure

Sponsors

Taizhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, female patients; 2. ASA physical status classification ?–?; 3. Patients identified as being at high risk of postoperative vomiting (preoperative Apfel score = 3); 4. Body Mass Index (BMI) 18.5-30 kg/m²; 5. Hospital stay > 48 hours; 6. Surgical duration < 2 hours.

Exclusion criteria

Exclusion criteria: 1. Inability to communicate preoperatively due to cognitive impairment or language barrier; 1.? Preoperative history of chronic pain or opioid abuse; 2. Patients with preoperative gastrointestinal or other related diseases prone to causing vomiting; 3.? History of drug use and/or alcohol abuse within the past 3 months; 4.? Patients who are expected to be unable to assess pain intensity postoperatively or to be transferred to the ICU; 6. Patients with expected intraoperative blood loss > 1000 ml or other serious complications during surgery; 5.? Severe systemic diseases involving the heart, lungs, liver, kidneys, etc. 6. Patients with central nervous system diseases or mental system disorders.

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale Score for Postoperative Nausea and Vomiting;

Secondary

MeasureTime frame
Postoperative Nausea and Vomiting Incidence;Numerical Rating Scale Pain Score;Recovery Room Stay Duration;Ramsay Sedation Scale Score;Quality of Recovery-15 Scale Score;Postoperative Adverse Reactions;Postoperative Satisfaction Score;

Countries

China

Contacts

Public ContactWang Wenwei

Taizhou First People's Hospital

www2229@163.com+86 576 8412 2522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026